Biotech | March 07, 2024
Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
India has reached to nearly 6,000 bio-startups from 50 in the past 10 years
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Subscribe To Our Newsletter & Stay Updated
